NCT00276796已完成2 期
A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 66
- 主要终点
- The frequency and duration of objective response
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel together with topotecan and cisplatin works in treating patients with advanced, persistent, or recurrent cervical cancer.
详细描述
OBJECTIVES:
Primary
- Estimate the antitumor activity of the combination of paclitaxel, topotecan, and cisplatin in patients with advanced, persistent, or recurrent carcinoma of the cervix.
- Determine the nature and degree of toxicity for this drug regimen in these patients.
Secondary
- Determine the duration of progression-free survival and overall survival.
- Determine the impact of prior chemoradiation on response to treatment.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Advanced, persistent, or recurrent squamous or nonsquamous cell carcinoma of the cervix with documented disease progression
- •Histologic confirmation of the original primary tumor is required
- •Disease must be measurable in at least one dimension by conventional techniques, including palpation, plain x-ray, CT scan, or MRI
- •Measurable disease is defined as at least one lesion that can be accurately measured
- •Each lesion must be ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
- •Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days after completion of radiation therapy
- •PATIENT CHARACTERISTICS:
- •GOG performance status 0-2
- •Platelet count ≥ 100,000/mm^3
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Creatinine ≤ 1.5 times upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 times ULN
- •SGOT and alkaline phosphatase ≤ 2.5 times ULN
- •Neuropathy (sensory and motor) ≤ grade 1
- •No active infection requiring antibiotics
- •No evidence of more than one malignancy present within the past 5 years
- •Nonmelanoma skin cancer allowed
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •No prior therapy with cytotoxic drugs for advanced or recurrent cervical carcinoma
- •Prior cisplatin as a radiosensitizer for primary treatment of disease allowed
- •No previous cancer treatment that contraindicates study treatment
- •No prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of cervical cancer
- •No prior chemotherapy for any abdominal or pelvic tumor except for the treatment of cervical cancer
- •Recovered from effects of recent surgery, radiotherapy, or other therapy
- •At least 4 weeks since prior radiotherapy
- •More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin and free of recurrent or metastatic disease
- •More than 3 years since prior adjuvant chemotherapy for localized breast cancer provided patient is free of recurrent or metastatic disease
- •No hormonal therapy directed at the malignant tumor within the past week
- •Concurrent hormone replacement therapy is permitted
- •No concurrent amifostine or other protective reagents
排除标准
- 未提供
结局指标
主要结局
The frequency and duration of objective response
The frequency and severity of observed adverse effects
次要结局
- Progression-free survival and overall survival
- Prognostic factor: prior chemoradiation
研究者
相似试验
撤回
2 期
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate CancerProstate CancerNCT00084565Fox Chase Cancer Center
终止
2 期
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast CancerStage IV Breast CancerRecurrent Breast CancerBreast CancerNCT01009983Wake Forest University Health Sciences14
已完成
2 期
Combination Chemotherapy for Patients With Brain CancerBrain and Central Nervous System TumorsNCT00002814Dartmouth-Hitchcock Medical Center20
已完成
2 期
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By SurgeryLung CancerNCT00281970Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50
已完成
1 期
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerDrug/Agent Toxicity by Tissue/OrganRadiation ToxicityLung CancerNCT00006012Alliance for Clinical Trials in Oncology73